Welcome to our dedicated page for Mind Medicine SEC filings (Ticker: MNMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trying to pinpoint LSD-derived trial costs or the latest patent updates in Mind Medicine’s dense reports can feel overwhelming. Each Form 10-Q details multiple study cohorts, while a single 10-K may span 250 pages of neuropharmacology and cash-runway math. If you have ever searched “Mind Medicine SEC filings explained simply,” you already know the challenge.
Stock Titan’s AI tackles that complexity head-on. Our platform delivers AI-powered summaries that translate biotech jargon into clear takeaways—whether you need the Mind Medicine quarterly earnings report 10-Q filing highlights or a Mind Medicine annual report 10-K simplified. Real-time alerts surface Mind Medicine insider trading Form 4 transactions; interactive dashboards compare R&D spend against previous quarters; and plain-English notes flag FDA correspondence disclosed in an 8-K.
Here’s how investors use the page:
- Receive Mind Medicine Form 4 insider transactions real-time to monitor executive buying and selling.
- Dive into Mind Medicine earnings report filing analysis to assess cash runway before the next Phase II readout.
- Review the Mind Medicine proxy statement executive compensation section without combing through proxy boilerplate.
- Get the Mind Medicine 8-K material events explained whenever the company issues a trial-halt or financing update.
- Leverage our natural-language layer for understanding Mind Medicine SEC documents with AI—no accounting degree required.
From Mind Medicine executive stock transactions Form 4 to nuanced risk-factor changes, every filing arrives within seconds of hitting EDGAR, accompanied by concise, expert context. Save hours, spot critical data quickly, and make informed biotech decisions—all in one place.
Mind Medicine (MindMed) Inc. (MNMD) – Form 4 insider transaction:
Chief Legal Officer Mark Sullivan reported the sale of 11,491 common shares on 25-Jun-2025. The shares were automatically sold (transaction code “S”) to cover withholding-tax liabilities triggered by the settlement of vested RSUs. The disposition was executed under a Rule 10b5-1 plan adopted 14-Mar-2024, indicating the trade was pre-scheduled and not discretionary.
The weighted-average sales price was $6.80, with individual trades carried out between $6.67 and $7.03. After the sale, Sullivan directly owns 305,130 shares, meaning the transaction reduced his position by roughly 3.6 %. No derivative securities were involved, and the filing was signed on 26-Jun-2025.
- The activity appears routine, tax-driven and represents a small fraction of the executive’s holdings.
- Provides investors with an indicative trading range for MNMD at the end of June 2025.
Given the limited size and tax-related nature, the sale is unlikely to carry significant fundamental implications, though it is the first insider disposition tied to this RSU vesting cycle.
Mind Medicine (MindMed) Chief Medical Officer Daniel Karlin reported a Form 4 filing on June 28, 2025, disclosing a transaction that occurred on June 25, 2025. The insider sold 7,848 common shares at a weighted average price of $6.80 per share, with individual transaction prices ranging from $6.67 to $7.03.
Key details of the transaction:
- The sale was executed to satisfy tax withholding obligations related to vested restricted stock units
- The transaction was conducted under a Rule 10b5-1 plan adopted on June 14, 2022
- Following the transaction, Karlin maintains direct ownership of 438,329 common shares
- The sale was executed as a "sell-to-cover" transaction, which is a common method for handling tax obligations on equity compensation
This transaction appears to be a routine share sale for tax purposes rather than a discretionary trading decision by the insider.
MindMed (NASDAQ: MNMD) filed a Form 4 showing CEO & Director Robert Barrow sold 26,491 common shares on 25 Jun 2025 at a weighted-average price of $6.80. The sale, made under a pre-arranged Rule 10b5-1 plan, was solely to cover withholding taxes on recently vested RSUs. After the transaction, Barrow retains 830,065 shares of MindMed. No other insider trades or material changes were disclosed.
A Form 144 filing from Mind Medicine (MindMed) indicates a proposed sale of 7,848 shares of common stock with an aggregate market value of $53,387.59 by an insider. The shares are to be sold through Morgan Stanley Smith Barney LLC on the NASDAQ exchange, with an approximate sale date of June 25, 2025.
The securities were originally acquired through restricted stock vesting under a registered plan as compensation on June 25, 2025. The total outstanding shares of the company are reported at 75,553,266.
- Share Price (implied): ~$6.80 per share
- Sale represents approximately 0.01% of total outstanding shares
- No other securities were reported as sold by the insider during the past 3 months
Form 144 is required for proposed sales of restricted securities by affiliates, indicating this is likely an insider or executive transaction.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) has filed a Form S-8 to register up to 16,367,773 additional common shares for employee equity compensation programs. The filing covers three components:
- 2025 Equity Incentive Plan: 4,500,000 newly reserved shares plus up to 9,318,090 "Outstanding Award Shares" that could migrate from retired legacy plans if the underlying awards are forfeited or lapse.
- Performance & Restricted Share Unit (PRSU) Plan: 147,133 shares for ongoing PSU/RSU grants under the existing PRSU plan.
- Inducement Grants: 2,402,550 shares for option, RSU and PSU awards issued to new hires under Nasdaq Listing Rule 5635(c)(4).
The Board approved the 2025 Plan on 22 April 2025 and shareholders ratified it on 12 June 2025. The registration enables the company to issue shares quickly when awards vest or options are exercised, without additional SEC registration hurdles. Standard incorporation-by-reference language brings the company’s latest 10-K, 10-Q and specified 8-Ks into the prospectus, and the filing reiterates indemnification provisions for directors and officers under British Columbia law.
Key investor takeaway: The registration itself does not raise capital but it does increase the pool of shares that can enter the market through employee exercises or vesting, representing potential dilution of approximately 4.8 % of the 338 million shares outstanding as of the last 10-Q (not included in the filing but cited here for context). The expanded equity capacity is intended to support talent attraction and retention during the company’s clinical development phase.
FAQ
What is the current stock price of Mind Medicine (MNMD)?
What is the market cap of Mind Medicine (MNMD)?
What is the primary focus of Mind Medicine Inc.?
How does Mind Medicine Inc. differentiate itself in the biotech industry?
What types of therapies are developed by Mind Medicine Inc.?
What is meant by the term 'psychoplastogens' in the context of Mind Medicine Inc.?
In which ways does Mind Medicine Inc. approach drug development?
How does the company manage regulatory challenges?
What is the significance of the company’s research in the broader mental health field?
How does Mind Medicine Inc. compare to other biotech companies in the same space?
